Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Angle Files De Novo Submission For Parsortix System In Breast Cancer

Executive Summary

The system has the potential to be the first FDA-cleared device for harvesting intact cancer cells from a blood sample for subsequent analysis.

You may also be interested in...



Angle Is Ready To Capitalize On Promise Of Capture Cell Technology

Angle PLC has published half year interim results which indicate it will capitalize on a new liquid biopsy market.

Angle Will Reshape Liquid Diagnostics By Capturing Circulating Tumor Cells

Following a successful fundraise, Angle is poised to further commercialize its proprietary cell-catching technology for cancer diagnosis

Qiagen’s Ambitions: Standing Alone And Strengthening Infectious Disease Portfolio

Qiagen official Antoine Marchal outlines how NeuModx will strengthen its position in the infectious disease space.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT142809

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel